Search results for "From ACP Journal Club"
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes
While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/01/12/10.htm
12 Jan 2018
In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors
Drinking red wine, rather than mineral water, with dinner every night for 2 years was associated with improvements in cholesterol markers in patients in Israel. A group assigned to white wine did not show significant differences on these markers from the water group.
https://diabetes.acponline.org/archives/2016/03/11/6.htm
11 Mar 2016
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics
A review looked at randomized trials that compared mortality rates among patients taking sulfonylureas versus several other classes of hypoglycemic drugs.
https://diabetes.acponline.org/archives/2017/05/12/6.htm
12 May 2017
Review: Intensive blood pressure control reduces retinopathy in diabetes
Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.
https://diabetes.acponline.org/archives/2015/07/10/5.htm
10 Jul 2015
Bariatric surgery improved HbA1c more than intensive medical therapy in obese patients with uncontrolled type 2 DM
Longer-term outcomes show that adding Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy to intensive medical therapy enabled more obese, type 2 diabetes patients to maintain glycemic control.
https://diabetes.acponline.org/archives/2014/09/12/6.htm
12 Sep 2014
In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y
The study's primary composite outcome was first occurrence of death from cardiovascular (CV) causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke.
https://diabetes.acponline.org/archives/2016/11/11/6.htm
11 Nov 2016
In type 2 diabetes, a primary care–led weight management program increased weight loss and diabetes remission at 2 years
Primary care practices that want to adopt such an intervention for their patients will need a dietician or practice nurse to deliver an intensive weight loss program, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/8.htm
13 Sep 2019
In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c
The hypoglycemia rate was higher in the first month after initiation of liraglutide, but the overall hypoglycemia rate over the 6-month follow-up was similar in liraglutide and placebo patients.
https://diabetes.acponline.org/archives/2016/11/11/5.htm
11 Nov 2016
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022